International nonproprietary name: difference between revisions
Diff·revision 2 → 3·04:08, 22 Oct 2024
Difference between revision 2 and revision 3 of International nonproprietary name. 12 lines changed; the page grew by 727 bytes.
| Revision 2 — 11:14, 10 Oct 2024 CagriCass (talk) de-duplicate a repeated sentence 1,106 bytes ±0 | Revision 3 — 04:08, 22 Oct 2024 CiteBot (talk) bot: add drug-class category 1,833 bytes +727 | ||
|---|---|---|---|
| 11 | INNs are constructed from a distinctive prefix, chosen to be pronounceable and unlike existing names, and a stem indicating pharmacological class. The stem is the informative part: '''-glutide''' denotes a GLP-1 analogue, and '''-tide''' more broadly denotes a peptide.{{r|who_inn}} | 11 | INNs are constructed from a distinctive prefix, chosen to be pronounceable and unlike existing names, and a stem indicating pharmacological class. The stem is the informative part: '''-glutide''' denotes a GLP-1 analogue, and '''-tide''' more broadly denotes a peptide.{{r|who_inn}} |
| 12 | 12 | ||
| + | 13 | == Stems relevant here == | |
| + | 14 | | Stem | Meaning | Examples | | |
| + | 15 | |---|---|---| | |
| + | 16 | | -tide | Peptide | Many | | |
| + | 17 | | -glutide | GLP-1 analogue | [[Semaglutide]], [[Liraglutide]], [[Dulaglutide]] | | |
| + | 18 | | -dutide | Dual or multi-receptor glucagon-family agonist | [[Survodutide]], [[Efinopegdutide]] | | |
| + | 19 | | -tirzepatide | Assigned individually | [[Tirzepatide]] | | |
| + | 20 | | -glipron | Non-peptide GLP-1 receptor agonist | [[Orforglipron]] | | |
| + | 21 | | -lintide | Amylin analogue | [[Cagrilintide]] | | |
| + | 22 | ||
| + | 23 | The distinction between ''-glutide'' and ''-dutide'' encodes the difference between a GLP-1 analogue and a multi-receptor glucagon-family agonist, which is a real pharmacological distinction rather than a naming convenience. See [[Dual incretin agonist]].{{r|who_inn}} | |
| + | 24 | ||
| 13 | == References == | 25 | == References == |
| 14 | {{reflist}} | 26 | {{reflist}} |